Na Zhang1, Fei Li1, Juanyu Gao2, Shibao Zhang1, Qihong Wang3. 1. Department of Urology, Ji'nan Central Hospital Affiliated to Shandong University, No. 105 Jiefang Road, Lixia District, Jinan, 250013, Shandong, China. 2. Department of Cardiology, Ji'nan Central Hospital Affiliated to Shandong University, Jinan, 250013, Shandong, China. 3. Department of Urology, Ji'nan Central Hospital Affiliated to Shandong University, No. 105 Jiefang Road, Lixia District, Jinan, 250013, Shandong, China. Wangqihong1200@163.com.
Abstract
BACKGROUND: Bladder cancer is the 10th common cancer worldwide. Osteopontin has been found to enhance cell proliferation, metastasis and invasion in various human tumors. OBJECTIVE: To investigate the roles of osteopontin in bladder cancer. METHODS: The RNA interference and overexpression of osteopontin were performed in bladder cancer cell lines (T24 and SCaBER). Cell proliferation and apoptosis were measured using CCK-8 assay and flow cytometry, respectively. Cell invasion was determined using transwell assay. RESULTS: Osteopontin was highly expressed in bladder cancer tissues in comparison with the adjacent normal tissues. Its high expression significantly correlated with high histologic grade, high TNM stage (III and IV) and poor prognosis. For T24 cells with osteopontin interference and SCaBER cells with osteopontin overexpression, cell proliferation was significantly inhibited (3.58-fold vs. 5.62-fold) and enhanced (7.81-fold vs. 5.29-fold), respectively. The apoptosis portion of T24 cells significantly increased from 4.48 to 10.75%, and that of SCaBER cells significantly declined from 7.33 to 4.01%. The invaded T24 and SCaBER cells significantly decreased to 52.0% and increased to 2.0-fold, respectively. Osteopontin overexpression enhanced the expression (1.54-fold and 2.39-fold; 2.33-fold and 2.05-fold) and activation (1.80-fold and 1.96-fold; 2.00-fold and 2.59-fold) of JAK1 and STAT1 in two cell lines of bladder cancer. CONCLUSION: Osteopontin might enhance proliferation, inhibit apoptosis and accelerate invasion and thus promote the development and metastasis of bladder cancer, and osteopontin's functions might be mediated by activating JAK1/STAT1 signaling pathway.
BACKGROUND:Bladder cancer is the 10th common cancer worldwide. Osteopontin has been found to enhance cell proliferation, metastasis and invasion in various humantumors. OBJECTIVE: To investigate the roles of osteopontin in bladder cancer. METHODS: The RNA interference and overexpression of osteopontin were performed in bladder cancer cell lines (T24 and SCaBER). Cell proliferation and apoptosis were measured using CCK-8 assay and flow cytometry, respectively. Cell invasion was determined using transwell assay. RESULTS:Osteopontin was highly expressed in bladder cancer tissues in comparison with the adjacent normal tissues. Its high expression significantly correlated with high histologic grade, high TNM stage (III and IV) and poor prognosis. For T24 cells with osteopontin interference and SCaBER cells with osteopontin overexpression, cell proliferation was significantly inhibited (3.58-fold vs. 5.62-fold) and enhanced (7.81-fold vs. 5.29-fold), respectively. The apoptosis portion of T24 cells significantly increased from 4.48 to 10.75%, and that of SCaBER cells significantly declined from 7.33 to 4.01%. The invaded T24 and SCaBER cells significantly decreased to 52.0% and increased to 2.0-fold, respectively. Osteopontin overexpression enhanced the expression (1.54-fold and 2.39-fold; 2.33-fold and 2.05-fold) and activation (1.80-fold and 1.96-fold; 2.00-fold and 2.59-fold) of JAK1 and STAT1 in two cell lines of bladder cancer. CONCLUSION:Osteopontin might enhance proliferation, inhibit apoptosis and accelerate invasion and thus promote the development and metastasis of bladder cancer, and osteopontin's functions might be mediated by activating JAK1/STAT1 signaling pathway.
Authors: Youn Hee Joung; Yoon Mi Na; Young Bum Yoo; Pramod Darvin; Nipin Sp; Dong Young Kang; Sang Yoon Kim; Hong Sup Kim; Yoon Hee Choi; Hak Kyo Lee; Kyung Do Park; Byung Wook Cho; Heui Soo Kim; Jong Hwan Park; Young Mok Yang Journal: Int J Oncol Date: 2014-01-08 Impact factor: 5.650
Authors: Christina Greenwood; Gergana Metodieva; Khalid Al-Janabi; Berthold Lausen; Louise Alldridge; Lin Leng; Richard Bucala; Nelson Fernandez; Metodi V Metodiev Journal: J Proteomics Date: 2011-12-08 Impact factor: 4.044
Authors: Yiyang Sun; Mai-Kim Cheng; Thomas R L Griffiths; J Kilian Mellon; Bao Kai; Marina Kriajevska; Margaret M Manson Journal: Curr Cancer Drug Targets Date: 2013-01 Impact factor: 3.428